文献速递肝病

增强肝纤维化检测在2型糖尿病患者中的准确性及其临床意义

Accuracy of the Enhanced Liver Fibrosis Test in Patients With Type 2 Diabetes Mellitus and Its Clinical Implications.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-12-02

本研究纳入1228例经活检证实为非酒精性脂肪性肝病的患者,比较增强肝纤维化(ELF)检测与FIB-4指数及NAFLD纤维化评分(NFS)对进展性纤维化的诊断性能。结果显示,无论是否合并2型糖尿病,ELF检测的曲线下面积均高于FIB-4和NFS;在2型糖尿病患者中,ELF低 cut-off 值的假阴性率可接受,且敏感性和阴性预测值高。

要点

  • 在合并或不合并2型糖尿病的NAFLD患者中,ELF检测预测进展性纤维化的AUC均高于FIB-4和NFS。
  • 2型糖尿病患者中,ELF低 cut-off 值(9.8)的假阴性率为6.7%,低于FIB-4(1.30,14.5%)和NFS(-1.455,12.4%)。
  • 倾向性评分匹配后,ELF低 cut-off 值的敏感性≥91.4%、阴性预测值≥96.8%,不受2型糖尿病存在与否影响。

核心结论

  • ELF检测在合并或不合并2型糖尿病的个体中对进展性纤维化具有高诊断性能,可能满足糖尿病和NAFLD患者准确评估肝纤维化的未满足医疗需求。

研究设计与样本

  • 研究纳入1228例经活检证实为非酒精性脂肪性肝病的患者,评估ELF检测预测进展性纤维化的诊断性能,并与FIB-4指数和NFS比较。

主要发现

  • 总体而言,ELF检测预测进展性纤维化的曲线下面积为0.828,高于FIB-4指数的0.727和NFS的0.733。
  • 在2型糖尿病患者中,ELF检测的曲线下面积为0.820,优于FIB-4指数的0.698和NFS的0.700。
  • 采用各无创检测的低 cut-off 值时,ELF检测(cut-off值9.8)的假阴性率为6.7%,FIB-4指数(1.30)为14.5%,NFS(-1.455)为12.4%。
  • 经倾向性评分匹配(匹配年龄、性别、体重指数和进展性纤维化患病率)后,ELF检测低 cut-off 值显示高敏感性(≥91.4%)和高阴性预测值(≥96.8%),无论是否合并2型糖尿病。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The diagnostic performance of the Fibrosis-4 (FIB-4) index and nonalcoholic fatty liver disease (NAFLD) fibrosis score (NFS) is poor in patients with type 2 diabetes mellitus (T2DM). We determined the usefulness of the Enhanced Liver Fibrosis (ELF) test in patients with T2DM. METHODS: A total of 1228 patients with biopsy-proven NAFLD were enrolled. The diagnostic performance of the ELF test for predicting advanced fibrosis in participants with or without T2DM was evaluated in comparison with the FIB-4 index and NFS. RESULTS: Overall, the area under the curve of the ELF test for predicting advanced fibrosis was greater (0.828) than that of the FIB-4 index (0.727) and NFS (0.733). The diagnostic performance of the ELF test (area under the curve, 0.820) was also superior to that of the FIB-4 index (0.698) and NFS (0.700) in patients with T2DM. With the low cutoff values for each noninvasive test, the ELF test provided an acceptable false negative rate (cutoff value 9.8, 6.7%) in this population, unlike the FIB-4 index (1.30, 14.5%) and NFS (-1.455, 12.4%). After propensity score matching to avoid selection bias including age, sex, body mass index, and the prevalence of advanced fibrosis, the ELF test with a low cutoff value showed a high sensitivity (≥91.4%) and a high negative predictive value (≥96.8%), irrespective of the presence or absence of T2DM. CONCLUSIONS: The high diagnostic performance of the ELF test for predicting advanced fibrosis in individuals with or without T2DM could address an unmet medical need for accurate assessment of liver fibrosis in patients with diabetes and NAFLD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Arai T, Takahashi H, Seko Y, et al. Accuracy of the Enhanced Liver Fibrosis Test in Patients With Type 2 Diabetes Mellitus and Its Clinical Implications. Clin Gastroenterol Hepatol. 2023. PMID: 38048934. doi:10.1016/j.cgh.2023.11.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。